HLA-A and melanoma: Studying MHC-I diversity in >1500 patients (mostly with melanoma and lung cancer) treated with immune checkpoint inhibitors, Chan and colleagues demonstrated that homozygosity at one MHC-I locus (either HLA-A, -B or -C) was associated with a significant reduction in overall survival, compared with the “full house” MHC-I [55].